Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m2: Subgroup Analysis of the Randomized CREDENCE Trial.
暂无分享,去创建一个
B. Zinman | C. Cannon | A. Levin | K. Mahaffey | G. Bakris | T. Greene | M. Jardine | V. Perkovic | D. Wheeler | B. Neal | D. de Zeeuw | H. Heerspink | G. Capuano | D. Charytan | C. Pollock | R. Agarwal | M. Oshima | Hong Zhang | N. Rosenthal | Robert Edwards | Richard Oh | A. Levin
[1] J. McMurray,et al. Dapagliflozin in Patients with Chronic Kidney Disease. , 2020, The New England journal of medicine.
[2] G. Laverman,et al. Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial. , 2020, The lancet. Diabetes & endocrinology.
[3] B. Zinman,et al. Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial. , 2020, Journal of the American Society of Nephrology : JASN.
[4] A. Magno,et al. SGLT2 Inhibitor–Induced Sympathoinhibition , 2020, JACC. Basic to translational science.
[5] Akshay S. Desai,et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. , 2019, The New England journal of medicine.
[6] B. Zinman,et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. , 2019, The New England journal of medicine.
[7] N. Ward,et al. SGLT2 Inhibitor–Induced Sympathoinhibition , 2019, JACC. Basic to translational science.
[8] B. Zinman,et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. , 2019, The New England journal of medicine.
[9] L. Navar,et al. Canagliflozin Prevents Intrarenal Angiotensinogen Augmentation and Mitigates Kidney Injury and Hypertension in Mouse Model of Type 2 Diabetes Mellitus , 2019, American Journal of Nephrology.
[10] G. Bakris,et al. Blood Pressure Lowering and Sodium-Glucose Co-transporter 2 Inhibitors (SGLT2is): More Than Osmotic Diuresis , 2019, Current Hypertension Reports.
[11] Marc P. Bonaca,et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials , 2019, The Lancet.
[12] J. Coresh,et al. Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency. , 2019, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[13] A. Sahebkar,et al. Effects of antidiabetic drugs on NLRP3 inflammasome activity, with a focus on diabetic kidneys. , 2019, Drug discovery today.
[14] K. Tsuchiya,et al. A reduced M1-like/M2-like ratio of macrophages in healthy adipose tissue expansion during SGLT2 inhibition , 2018, Scientific Reports.
[15] D. Wheeler,et al. Effects of the sodium–glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b–4 chronic kidney disease , 2018, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[16] B. Zinman,et al. The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) study rationale and design , 2018 .
[17] B. Zinman,et al. The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics , 2017, American Journal of Nephrology.
[18] Progression of Chronic Kidney Disease After Acute Kidney Injury: Role of Self-Perpetuating Versus Hemodynamic-Induced Fibrosis. , 2016, Hypertension.
[19] P. Heagerty,et al. Clinical Manifestations of Kidney Disease Among US Adults With Diabetes, 1988-2014. , 2016, JAMA.
[20] B. Brenner,et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy , 2002 .
[21] B. Brenner,et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. , 2001, The New England journal of medicine.
[22] E. Lewis,et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.
[23] A Fournier,et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. , 1994, The New England journal of medicine.
[24] R. Bain,et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. , 1993 .
[25] R. Bain,et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. , 1993, The New England journal of medicine.